Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Primary Purpose
Pediatric Renal Tumor, Metastatic Osteosarcoma, Metastatic Ewing Sarcoma
Status
Completed
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Indocyanine green
Sponsored by
About this trial
This is an interventional treatment trial for Pediatric Renal Tumor focused on measuring Indocyanine green, Near Infra-red fluoroscopy, pediatric, oncology, minimal access surgery, Wilms
Eligibility Criteria
Inclusion Criteria:
- Age between 1 day and 15 years 365 days
- Have a diagnosis of an intra-abdominal, retroperitoneal or intra-thoracic tumour or pulmonary metastases
- Require surgery as part of their treatment
- Tumour or metastasis suitable for MIS resection based on assessment of the pre-operative imaging
Exclusion Criteria:
- Allergic to ICG
- Allergic to iodine or iodides
- Due to receive radioactive iodine as part of a treatment
- Hyperthyroidism
- Unwilling to participate
- Chronic Kidney Disease stage V
Sites / Locations
- Birmingham children's hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Single Arm
Arm Description
Injection of Indocyanine Green at doses detailed on summary of product characteristics for each age range
Outcomes
Primary Outcome Measures
Number of fluorescent nodes resected during minimally invasive tumour nephrectomy
Number of fluorescent nodes resected per patient
Is Fluorescent guided tumour resection easier than non-fluorescent guided.
Subjective surgeon analysis of intra-operative conditions on a Likert scale per patient
To evaluate if NIRF and ICG allow detection of pulmonary metastases
Comparison of number of lesions seen on CT with those seen with fluoroscopy per patient
Secondary Outcome Measures
To evaluate if fluorescent nodes or metastases are more likely to contain viable tumour
Number of fluorescent nodes and metastases containing viable tumour per patient
Full Information
NCT ID
NCT04854018
First Posted
February 5, 2021
Last Updated
August 9, 2023
Sponsor
Birmingham Women's and Children's NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT04854018
Brief Title
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Official Title
An Open Label, Single Centre, Single Arm, Prospective Feasibility Study Evaluating the Effectiveness of Near-infrared Fluorescence (NIRF) Using Indo-cyanine Green (ICG) in Minimally Invasive Paediatric Oncology Surgery (MIS)
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
April 30, 2021 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
September 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Birmingham Women's and Children's NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent during surgery. It has been used increasingly in the field of adult oncology surgery and has been shown to increase the efficacy of this surgery.
The aim of this study is to evaluate the use of NIRF and ICG during specific minimally invasive surgery (MIS) procedures within paediatric oncology surgery. Their use will complement existing surgical techniques rather than replace them.
Given the published advantages in adults this study aims to provide evidence of feasibility in the paediatric patients with cancer.
Detailed Description
The purpose of this study is to show the feasibility of using ICG in combination with NIRF and MIS in paediatric oncology surgery. It has been used increasingly over the past few years for a range of adult oncology surgical indications including tumour margin identification, lymph node identification and pulmonary metastectomy. It will be investigated in three groups of patients in our study:
Tumour margin identification-Identifying the margins of a tumour intra-operatively is crucial for many paediatric cancers. Incomplete resections or resections with involved margins often require upstaging of treatment with more intensive chemotherapy or radiotherapy. ICG will be injected intravenously and then NIRF will be used intermittently until fluorescence is achieved and an evaluation of the tumour and its margins will be performed.
Lymph node identification - It is standard of care for most oncology resections to remove lymph nodes that are suspected to be involved with tumour. Both SIOP and COG recommend the removal of 7 or more lymph nodes during a nephrectomy for Wilm's tumour although this is often not achieved. IGC will be injected directly into the tumour (or the adjacent tissue in 2-4 places) and then NIRF will be used intermittently until fluorescence is achieved. An evaluation of the tumour and any fluorescent lymph nodes will then take place and any fluorescent lymph nodes will be removed.
Pulmonary metastectomy - Many paediatric cancers including Wilm's tumour have a propensity to metastasise to the lungs. Removal of all lung metastases is important as it has the potential to down-stage tumours, obviating the need for pulmonary radiotherapy.
Modern radiology techniques can identify lesions as small as 1mm which are often not palpable at the time of surgery. Relying on finger palpation requires patients to have a thoracotomy with all of the associated complications. ICG will be injected intravenously and then NIRF will be combined with MIS to identify any fluorescent lesions. The location of any lesions will be compared with those seen on pre-surgical imaging (current standard practice).
For all three groups of patients, the use of ICG and NIRF will complement rather than replace existing surgical technique in patients who require surgery already. Data will be collected on the number of lesions which do/do not fluoresce as well as the histology of lesions removed. They will be separated into lesions which do not fluoresce, lesions which were removed before fluorescence (they will be checked for ex-vivo fluorescence) and fluorescing lesions so that the histological characteristics of each group can be compared.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pediatric Renal Tumor, Metastatic Osteosarcoma, Metastatic Ewing Sarcoma, Pulmonary Metastasis, Rhabdomyosarcoma, Non-Rhabdo. Soft Tissue Sarcoma
Keywords
Indocyanine green, Near Infra-red fluoroscopy, pediatric, oncology, minimal access surgery, Wilms
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
open label, single centre, single arm, prospective feasibility study
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Single Arm
Arm Type
Experimental
Arm Description
Injection of Indocyanine Green at doses detailed on summary of product characteristics for each age range
Intervention Type
Drug
Intervention Name(s)
Indocyanine green
Other Intervention Name(s)
Verdye, Diagnostic Green
Intervention Description
Intravenous or intraparenchymal injection
Primary Outcome Measure Information:
Title
Number of fluorescent nodes resected during minimally invasive tumour nephrectomy
Description
Number of fluorescent nodes resected per patient
Time Frame
Until the end of surgery, 2 hours
Title
Is Fluorescent guided tumour resection easier than non-fluorescent guided.
Description
Subjective surgeon analysis of intra-operative conditions on a Likert scale per patient
Time Frame
until the end of surgery, 2 hours
Title
To evaluate if NIRF and ICG allow detection of pulmonary metastases
Description
Comparison of number of lesions seen on CT with those seen with fluoroscopy per patient
Time Frame
until the end of surgery, 2 hours
Secondary Outcome Measure Information:
Title
To evaluate if fluorescent nodes or metastases are more likely to contain viable tumour
Description
Number of fluorescent nodes and metastases containing viable tumour per patient
Time Frame
until histopathology is reported, 2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age between 1 day and 15 years 365 days
Have a diagnosis of an intra-abdominal, retroperitoneal or intra-thoracic tumour or pulmonary metastases
Require surgery as part of their treatment
Tumour or metastasis suitable for MIS resection based on assessment of the pre-operative imaging
Exclusion Criteria:
Allergic to ICG
Allergic to iodine or iodides
Due to receive radioactive iodine as part of a treatment
Hyperthyroidism
Unwilling to participate
Chronic Kidney Disease stage V
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Max Pachl
Organizational Affiliation
Birmingham Women's and Children's NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Birmingham children's hospital
City
Birmingham
ZIP/Postal Code
B4 6NH
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34606881
Citation
Pachl MJ. Fluorescent Guided Lymph Node Harvest in Laparoscopic Wilms Nephroureterectomy. Urology. 2021 Dec;158:189-192. doi: 10.1016/j.urology.2021.09.015. Epub 2021 Oct 2.
Results Reference
derived
Learn more about this trial
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
We'll reach out to this number within 24 hrs